# MannKind to Participate in Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/MNKD/mannkind-to-participate-in-upcoming-investor-conferences Ticker: MNKD Company: MannKind Source: MannKind Published: 2026-03-04 14:00 EST Original Source URL: https://investors.mannkindcorp.com ## Summary DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris ## Article Body DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris ## Recent Company News - 2026-06-03 10:05 EST — [MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF](https://biopharmsignal.com/news/MNKD/mannkind-enters-data-rich-development-period-with-completion-of-randomization-in-phase-1b-inflo-1-study-and-enrollment-of-first-patient-in-phase-2-inflo-2-trial-for-nintedanib-dpi-in-patients-with-ipf) — Source: MannKind - 2026-05-29 18:00 EST — [MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval](https://biopharmsignal.com/news/MNKD/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval) — Source: MannKind - 2026-05-29 16:30 EST — [MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes](https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-afrezzar-the-first-and-only-inhaled-mealtime-insulin-for-use-in-children-and-adolescents-aged-6-and-older-living-with-diabetes) — Source: MannKind - 2026-05-27 20:00 EST — [MannKind to Present at Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/MNKD/mannkind-to-present-at-jefferies-global-healthcare-conference) — Source: MannKind - 2026-05-27 13:05 EST — [MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems](https://biopharmsignal.com/news/MNKD/mannkind-to-showcase-new-data-at-ada-2026-advancing-understanding-of-inhaled-insulin-afrezzar-in-pediatric-care-pregnancy-and-use-with-automated-insulin-delivery-aid-systems) — Source: MannKind ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)